Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Chinese Medicine
Published in: Chinese Medicine 1/2013

Open Access 01-12-2013 | Research

Biotransformation of ginsenoside Rb1 via the gypenoside pathway by human gut bacteria

Authors: Hong Shen, Weng-Im Leung, Jian-Qing Ruan, Song-Lin Li, JackyPui-Cheong Lei, Yi-Tao Wang, Ru Yan

Published in: Chinese Medicine | Issue 1/2013

Login to get access

Abstract

Background

Bacterial conversion of ginsenosides is crucial for the health-promoting effects of ginsenosides. Previous studies on the biotransformation of ginsenoside Rb1 (Rb1) by gut bacteria have focused on the ginsenoside Rd (Rd) pathway (Rb1 → Rd → ginsenoside F2 (F2) → compound K (Cpd K)). This study aims to examine the gypenoside pathway in human gut bacteria in vitro.

Methods

The metabolic pathways of ginsenoside Rb1 and its metabolites ginsenoside Rd and gypenoside XVII in human gut bacteria were investigated by incubating the compounds anaerobically with pooled or individual gut bacteria samples from healthy volunteers. Ginsenoside Rb1, the metabolites generated by human gut bacteria, and degraded products in simulated gastric fluid (SGF) were qualitatively analyzed using an LC/MSD Trap system in the negative ion mode and quantitatively determined by HPLC-UV analysis.

Results

When incubated anaerobically with pooled gut bacteria, Rb1 generated five metabolites, namely Rd, F2, Cpd K, and the rare gypenosides XVII (G-XVII) and LXXV (G-LXXV). The gypenoside pathway (Rb1 → G-XVII → G-LXXV → Cpd K) was rapid, intermediate, and minor, and finally converted Rb1 to Cpd K via G-XVII → F2 (major)/G-LXXV (minor). Both the Rd and gypenoside pathways exhibited great inter-individual variations in age-and sex-independent manners (P > 0.05). Rb1 was highly acid-labile and degraded rapidly to form F2, ginsenoside Rg3, ginsenoside Rh2, and Cpd K, but did not generate the gypenosides in SGF. The formation of the gypenosides might be explained by the involvement of a gut bacteria-mediated enzymatic process.

Conclusions

Rb1 was metabolized to G-XVII, F2 (major) or G-LXXL (minor), and finally Cpd K by human gut bacteria in vitro.
Appendix
Available only for authorised users
Literature
1.
Yang WZ, Ye M, Qiao X, Liu CF, Miao WJ, Bo T, Tao HY, Guo DA: A strategy for efficient discovery of new natural compounds by integrating orthogonal column chromatography and liquid chromatography/mass spectrometry analysis: its application in Panax ginseng, Panax quinquefolium and Panax notoginseng to characterize 437 potential new ginsenosides. Anal Chim Acta. 2012, 739: 56-66.CrossRefPubMed
2.
Shi W, Wang YT, Li J, Zhang HQ, Ding L: Investigation of ginsenosides in different parts and ages of Panax ginseng. Food Chem. 2007, 102: 664-668. 10.1016/j.foodchem.2006.05.053.CrossRef
3.
Wang CZ, Wu JA, McEntee E, Yuan CS: Saponins composition in American Ginseng leaf and berry assayed by high-performance liquid chromatography. J Agric Food Chem. 2006, 6: 2261-2266.CrossRef
4.
Xie YY, Luo D, Cheng YJ, Ma JF, Wang YM, Liang QL, Luo GA: Steaming-induced chemical transformations and holistic quality assessment of red Ginseng derived from Panax ginseng by means of HPLC-ESI-MS/MSn-based multicomponent quantification fingerprint. J Agric Food Chem. 2012, 33: 8213-8224.CrossRef
5.
Jiang Z, Wang Y, Zhang X, Peng T, Lu Y, Leng J, Xie Q: Preventive and therapeutic effects of ginsenoside rb1 for neural injury during cerebral infarction in rats. Am J Chin Med. 2013, 2: 341-352.CrossRef
6.
Shen L, Xiong Y, Wang DQ, Howles P, Basford JE, Wang J, Xiong YQ, Hui DY, Woods SC, Liu M: Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats. J Lipid Res. 2013, 5: 1430-1438.CrossRef
7.
Li QY, Chen L, Fu WH, Li ZD, Wang B, Shi XJ, Zhong MK: Ginsenoside Rb1 inhibits proliferation and inflammatory responses in rat aortic smooth muscle cells. J Agric Food Chem. 2011, 11: 6312-6318.CrossRef
8.
VanDuynhoven J, Vaughan EE, Jacobs DM, Kemperman RA, Van Velzen EJ, Gross G, Roger LC, Possemiers S, Smilde AK, Doré J, Westerhuis JA, Van de Wiele T: Metabolic fate of polyphenols in the human superorganism. Proc Natl Acad Sci U S A. 2011, 108: 4531-4538. 10.1073/pnas.1000098107.CrossRef
9.
Hidalgo M, Oruna-Concha MJ, Kolida S, Walton GE, Kallithraka S, Spencer JP, de Pascual-Teresa S: Metabolism of anthocyanins by human gut microflora and their influence on gut bacterial growth. J Agric Food Chem. 2012, 15: 3882-3890.CrossRef
10.
Sánchez-Patán F, Cueva C, Monagas M, Walton GE, Gibson GR, Quintanilla-López JE, Lebrón-Aguilar R, Martín-Álvarez PJ, Moreno-Arribas MV, Bartolomé B: In vitro fermentation of a red wine extract by human gut microbiota: changes in microbial groups and formation of phenolic metabolites. J Agric Food Chem. 2012, 9: 2136-2147.CrossRef
11.
Selma MV, Espín JC, Tomás-Barberán FA: Interaction between phenolics and gut microbiota: role in human health. J Agric Food Chem. 2009, 15: 6485-6501.CrossRef
12.
Liu H, Yang J, Du F, Gao X, Ma X, Huang Y, Xu F, Niu W, Wang F, Mao Y, Sun Y, Lu T, Liu C, Zhang B, Li C: Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos. 2009, 37: 2290-2298. 10.1124/dmd.109.029819.CrossRefPubMed
13.
Wakabayashi C, Hasegawa H, Murata J, Saiki I: In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol Res. 1997, 9: 411-417.PubMed
14.
Lee GW, Yoo MH, Shin KC, Kim KR, Kim YS, Lee KW, Oh DK: β-Glucosidase from Penicillium aculeatum hydrolyzes exo-, 3-O-, and 6-O-β-glucosides but not 20-O-β-glucoside and other glycosides of ginsenosides. Appl Microbiol Biotechnol. 2013, DOI: 10.1007/s00253-013-4828-7CrossRef
15.
Lee IK, Kang KA, Lim CM, Kim KC, Kim HS, Kim DH, Kim BJ, Chang WY, Choi JH, Hyun JW: Compound K, a metabolite of ginseng saponin, induces mitochondria-dependent and caspase-dependent apoptosis via the generation of reactive oxygen species in human colon cancer cells. Int J Mol Sci. 2011, 11: 4916-4931.CrossRef
16.
Niu T, Smith DL, Yang Z, Gao S, Yin T, Jiang ZH, You M, Gibbs RA, Petrosino JF, Hu M: Bioactivity and bioavailability of ginsenosides are dependent on the glycosidase activities of the A/J mouse intestinal microbiome defined by pyrosequencing. Pharm Res. 2013, 30: 836-846. 10.1007/s11095-012-0925-z.PubMedCentralCrossRefPubMed
17.
Hasegawa H: Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci. 2004, 95: 153-157. 10.1254/jphs.FMJ04001X4.CrossRefPubMed
18.
Hasegawa H, Sung JH, Matsumiya S, Uchiyama M: Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 1996, 62: 453-457. 10.1055/s-2006-957938.CrossRefPubMed
19.
Hasegawa H, Sung JH, Benno Y: Role of human intestinal prevotella oris in hydrolyzing ginseng saponins. Planta Med. 1997, 63: 436-440. 10.1055/s-2006-957729.CrossRefPubMed
20.
Chen GT, Song Y, Lu ZQ, Zhang JQ, Huang HL, Wu LJ, Guo DA: Microbial transformation of ginsenoside Rb1 by Acremonium strictum. Appl Microbiol Biotechnol. 2008, 77: 1345-1350. 10.1007/s00253-007-1258-4.CrossRefPubMed
21.
Hou JG, Xue JJ, Sun MQ, Wang CY, Liu L, Zhang DL, Lee MR, Gu LJ, Wang CL, Wang YB, Zheng Y, Li W, Sung CK: Highly selective microbial transformation of major ginsenoside Rb1 to gypenoside LXXV by Esteya vermicola CNU120806. J Appl Microbiol. 2012, 113: 807-814. 10.1111/j.1365-2672.2012.05400.x.CrossRefPubMed
22.
Zhao X, Gao J, Song C, Fang Q, Wang N, Zhao T, Liu D, Zhou Y: Fungal sensitivity to and enzymatic deglycosylation of ginsenosides. Phytochemistry. 2012, 78: 65-71.CrossRefPubMed
23.
Karikura M, Miyase T, Tanizawa H, Taniyama T, Takino Y: Studies on absorption, distribution, excretion and metabolism of ginseng saponins: VII: comparison of the decomposition modes of ginsenoside-Rb1 and -Rb2 in the digestive tract of rats. Biol Pharm Bull. 1991, 39: 2357-2361.
24.
Chen G, Yang M, Song Y, Lu Z, Zhang J, Huang H, Guan S, Wu L, Guo DA: Comparative analysis on microbial and rat metabolism of ginsenoside Rb1 by high-performance liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr. 2008, 22: 779-785. 10.1002/bmc.1001.CrossRefPubMed
25.
Lee J, Lee E, Kim D, Lee J, Yoo J, Koh B: Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. J Ethnopharmacol. 2009, 122: 143-148. 10.1016/j.jep.2008.12.012.CrossRefPubMed
26.
Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M: Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 2003, 31: 1065-1071. 10.1124/dmd.31.8.1065.CrossRefPubMed
27.
Ye R, Kong X, Yang Q, Zhang Y, Han J, Zhao G: Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice. Neuropharmacology. 2011, 61: 815-824. 10.1016/j.neuropharm.2011.05.029.CrossRefPubMed
28.
Qin R, Zhang J, Li C, Zhang X, Xiong A, Huang F, Yin Z, Li K, Qin W, Chen M, Zhang S, Liang L, Zhang H, Nie H, Ye W: Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats. Arch Pharm Res. 2012, 35: 1241-1250. 10.1007/s12272-012-0715-5.CrossRefPubMed
29.
Zhang GL, Deng JP, Wang BH, Zhao ZW, Li J, Gao L, Liu BL, Xiong JR, Guo XD, Yan ZQ, Gao GD: Gypenosides improve cognitive impairment induced by chronic cerebral hypoperfusion in rats by suppressing oxidative stress and astrocytic activation. Behav Pharmacol. 2011, 22: 633-644. 10.1097/FBP.0b013e32834afef9.CrossRefPubMed
30.
Pereira JM, Mejia-Ariza R, Ilevbare GA, McGettigan HE, Sriranganathan N, Taylor LS, Davis RM, Edgar KJ: Interplay of degradation, dissolution and stabilization of clarithromycin and its amorphous solid dispersions. Mol Pharm. 2013, DOI: 10.1021/mp400441d
31.
Pietta P, Mauri P, Rava A: Hydrolysis of ginsenosides in artificial gastric fluid monitored by HPLC. J Chromatogr. 1986, 362: 291-297.CrossRefPubMed
32.
Miyamoto E, Odashima S, Kitagawa I, Tsuji A: Stability kinetics of ginsenosides in aqueous solution. J Pharm Sci. 1984, 73: 409-410. 10.1002/jps.2600730334.CrossRefPubMed
33.
Zhou RN, Song YL, Ruan JQ, Wang YT, Yan R: Pharmacokinetic evidence on contribution of intestinal bacterial conversion to beneficial actions of astragaloside IV, a marker compound of Astragali Radix, in traditional oral use of the herb. Drug Metab Pharmacok. 2012, 27: 586-597. 10.2133/dmpk.DMPK-11-RG-160.CrossRef
34.
Kim KA, Jung IH, Park SH, Ahn YT, Huh CS, Kim DH: Comparative analysis of the gut microbiota in people with different levels of ginsenoside Rb1 degradation to compound K. PLoS One. 2013, 8: e62409-10.1371/journal.pone.0062409.PubMedCentralCrossRefPubMed
35.
Pharmacopoeia Commission of China: Appendix. Chinese Pharmacopoeia II. 2010, Beijing: China Medical Science Press, 85-
36.
Hasegawa H, Uchiyama M: Antimetastatic efficacy of orally administered ginsenoside Rb1 in dependence on intestinal bacterial hydrolyzing potential and significance of treatment with an active bacterial metabolite. Planta Med. 1998, 64: 696-700. 10.1055/s-2006-957560.CrossRefPubMed
37.
Qian TX, Jiang ZH, Cai ZW: High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat. Anal Biochem. 2006, 352: 87-96. 10.1016/j.ab.2006.02.025.CrossRefPubMed
38.
Jung IH, Lee JH, Hyun YJ, Kim DH: Metabolism of ginsenoside Rb1 by human intestinal microflora and cloning of its metabolizing β-D-glucosidase from Bifidobacterium longum H-1. Biol Pharm Bull. 2012, 35: 573-581. 10.1248/bpb.35.573.CrossRefPubMed
39.
Bae EA, Park SY, Kim DH: Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000, 23: 1481-1485. 10.1248/bpb.23.1481.CrossRefPubMed
40.
Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, De Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, Van Sinderen D, O’Connor M, Harnedy N, O’Connor K, Henry C, O’Mahony D, Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O’Toole PW: Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011, 108: 4586-4591. 10.1073/pnas.1000097107.PubMedCentralCrossRefPubMed
41.
Zhang X, Song F, Cui M, Liu Z, Liu S: Investigation of the hydrolysis of ginsenosides by high performance liquid chromatography-electospray ionization mass spectrometry. Planta Med. 2007, 73: 1225-1229. 10.1055/s-2007-981590.CrossRefPubMed
42.
Metadata
Title
Biotransformation of ginsenoside Rb1 via the gypenoside pathway by human gut bacteria
Authors
Hong Shen
Weng-Im Leung
Jian-Qing Ruan
Song-Lin Li
JackyPui-Cheong Lei
Yi-Tao Wang
Ru Yan
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Chinese Medicine / Issue 1/2013
Electronic ISSN: 1749-8546
DOI
https://doi.org/10.1186/1749-8546-8-22

Other articles of this Issue 1/2013

Chinese Medicine 1/2013 Go to the issue

Research

Effects of a fixed-intensity of endurance training and pistacia atlantica supplementation on ATP-binding cassette G4 expression

Research

Evaluation of seven DNA barcodes for differentiating closely related medicinal Gentiana species and their adulterants

Research

Flavonoids with α-glucosidase inhibitory activities and their contents in the leaves of Morus atropurpurea

Research

Changes in the contents of four active diterpenoids at different growth stages in Andrographis paniculata (Burm.f.) Nees (Chuanxinlian)

Research

Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity

Research

Puerarin promotes osteogenesis and inhibits adipogenesis in vitro